Dealing with Time in Health Economic Evaluation: Methodological Issues and Recommendations for Practice
暂无分享,去创建一个
Joost van Rosmalen | Anthony T. Newall | James F. O’Mahony | J. van Rosmalen | A. Newall | J. O’Mahony
[1] Murray Krahn,et al. Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--2. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[2] Mark Jit,et al. Economic evaluation of human papillomavirus vaccination in the United Kingdom , 2008, BMJ : British Medical Journal.
[3] J. Mauskopf,et al. Categorization of methods used in cost–effectiveness analyses of vaccination programs based on outcomes from dynamic transmission models , 2012, Expert review of pharmacoeconomics & outcomes research.
[4] Martin Hoyle,et al. Whose Costs and Benefits? Why Economic Evaluations Should Simulate Both Prevalent and All Future Incident Patient Cohorts , 2010, Medical decision making : an international journal of the Society for Medical Decision Making.
[5] Joost van Rosmalen,et al. A Mathematical Approach for Evaluating Markov Models in Continuous Time without Discrete-Event Simulation , 2013, Medical decision making : an international journal of the Society for Medical Decision Making.
[6] J. P. Dehollain,et al. Understanding the Cost-Effectiveness of Influenza Vaccination in Children: Methodological Choices and Seasonal Variability , 2013, PharmacoEconomics.
[7] G. Sanders,et al. Cost-Effectiveness in Health and Medicine , 2016 .
[8] Jagpreet Chhatwal,et al. Economic Evaluations with Agent-Based Modelling: An Introduction , 2015, PharmacoEconomics.
[9] N. Welton,et al. Estimation of Markov Chain Transition Probabilities and Rates from Fully and Partially Observed Data: Uncertainty Propagation, Evidence Synthesis, and Model Calibration , 2005, Medical decision making : an international journal of the Society for Medical Decision Making.
[10] M. Hoyle. Future Drug Prices and Cost-Effectiveness Analyses , 2012, PharmacoEconomics.
[11] Milton C Weinstein,et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies. , 2003, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[12] J. Killewo,et al. Epidemiology and demography in public health , 2010 .
[13] A. Zauber,et al. Multicohort Models in Cost-Effectiveness Analysis , 2013, Medical decision making : an international journal of the Society for Medical Decision Making.
[14] Karl Claxton,et al. Discounting and decision making in the economic evaluation of health-care technologies. , 2011, Health economics.
[15] Dennis G. Fryback,et al. Assessing the effectiveness of health interventions for cost-effectiveness analysis , 1997, Journal of General Internal Medicine.
[16] Nicholas R Latimer,et al. Survival Analysis for Economic Evaluations Alongside Clinical Trials—Extrapolation with Patient-Level Data , 2013, Medical decision making : an international journal of the Society for Medical Decision Making.
[17] J. Barendregt. The Half-Cycle Correction: Banish Rather Than Explain It , 2009, Medical decision making : an international journal of the Society for Medical Decision Making.
[18] Maureen A Smith,et al. Retrospective cost-effectiveness analysis of screening mammography. , 2006, Journal of the National Cancer Institute.
[19] Jonathan Karnon,et al. When to Use Discrete Event Simulation (DES) for the Economic Evaluation of Health Technologies? A Review and Critique of the Costs and Benefits of DES , 2014, PharmacoEconomics.
[20] C. Marra,et al. Effectiveness and Cost Effectiveness of Human Papillomavirus Vaccine , 2012, PharmacoEconomics.
[21] David M J Naimark,et al. Response to “The Life Table Method of Half-Cycle Correction: Getting It Right” , 2014, Medical decision making : an international journal of the Society for Medical Decision Making.
[22] Stephen Palmer,et al. The Half-Life of Truth: What Are Appropriate Time Horizons for Research Decisions? , 2008, Medical decision making : an international journal of the Society for Medical Decision Making.
[23] Jan J. Barendregt,et al. Chronic Disease Modeling , 2008 .
[24] M. Postma,et al. On discounting of health gains from human papillomavirus vaccination: effects of different approaches. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[25] S. Dewilde,et al. The Cost-Effectiveness of Screening Programs Using Single and Multiple Birth Cohort Simulations: A Comparison Using a Model of Cervical Cancer , 2004, Medical decision making : an international journal of the Society for Medical Decision Making.
[26] M S Thompson,et al. First principles of cost-effectiveness analysis in health. , 1979, Public health reports.
[27] Christopher McCabe,et al. Navigating Time and Uncertainty in Health Technology Appraisal: Would a Map Help? , 2013, PharmacoEconomics.
[28] K Cooper,et al. Choice of modelling technique for evaluating health care interventions , 2007, J. Oper. Res. Soc..
[29] S. Pauker,et al. The Markov Process in Medical Prognosis , 1983, Medical decision making : an international journal of the Society for Medical Decision Making.
[30] PREDICTING SURVIVAL IN COST-EFFECTIVENESS ANALYSES BASED ON CLINICAL TRIALS , 2003, International Journal of Technology Assessment in Health Care.
[31] E. Keeler,et al. Discounting of Life-Saving and Other Nonmonetary Effects , 1983 .
[32] J. Mauskopf,et al. Prevalence-based economic evaluation. , 1998, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[33] Stirling Bryan,et al. Modelling in the economic evaluation of health care: selecting the appropriate approach , 2004, Journal of health services research & policy.
[34] G. Loewenstein,et al. Time Discounting and Time Preference: A Critical Review , 2002 .
[35] J. Chhatwal,et al. Changing Cycle Lengths in State-Transition Models: Doing it the Right Way , 2014 .
[36] K. Claxton,et al. Budget allocation and the revealed social rate of time preference for health. , 2012, Health economics.
[37] M. Weinstein,et al. Foundations of cost-effectiveness analysis for health and medical practices. , 1977, The New England journal of medicine.
[38] Andrea Manca,et al. PCV59 Where Did the Time Go?: Temporal Uncertainty in Cost-Effectiveness Decision Models , 2012 .
[39] M. Gold,et al. Panel on cost-effectiveness in health and medicine. , 1996, Medical care.
[40] J. Berkhof,et al. How to screen for cervical cancer after HPV16/18 vaccination in The Netherlands. , 2009, Vaccine.
[41] D. Owens,et al. State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--3. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[42] J R Beck,et al. Markov Models in Medical Decision Making , 1993, Medical decision making : an international journal of the Society for Medical Decision Making.
[43] J. Habbema,et al. Practical implications of differential discounting in cost-effectiveness analyses with varying numbers of cohorts. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[44] Murray Krahn,et al. The Half-Cycle Correction Explained: Two Alternative Pedagogical Approaches , 2008, Medical decision making : an international journal of the Society for Medical Decision Making.
[45] G. Gazelle,et al. Use of modeling to evaluate the cost-effectiveness of cancer screening programs. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] S. Cantor,et al. Impact of Generic Drug Entry on Cost-Effectiveness Analysis , 2005, Medical decision making : an international journal of the Society for Medical Decision Making.
[47] Jonathan Karnon,et al. A Critique and Impact Analysis of Decision Modeling Assumptions , 2007, Medical decision making : an international journal of the Society for Medical Decision Making.
[48] A S Detsky,et al. Primer on Medical Decision Analysis: Part 2—Building a Tree , 1997, Medical decision making : an international journal of the Society for Medical Decision Making.
[49] H. Gravelle,et al. Discounting for health effects in cost-benefit and cost-effectiveness analysis. , 2001, Health economics.
[50] Andrew Briggs,et al. An Introduction to Markov Modelling for Economic Evaluation , 1998, PharmacoEconomics.
[51] D. Schopper,et al. Cost-effectiveness of opportunistic versus organised mammography screening in Switzerland. , 2009, European journal of cancer.
[52] Marta O. Soares,et al. Continuous Time Simulation and Discretized Models for Cost-Effectiveness Analysis , 2012, PharmacoEconomics.
[53] B. Standaert,et al. Population–versus Cohort–Based Modelling Approaches , 2012, PharmacoEconomics.
[54] P. Beutels,et al. Economic evaluations of implemented vaccination programmes: key methodological challenges in retrospective analyses. , 2014, Vaccine.
[55] W. Edmunds,et al. Economic Evaluation of Vaccination Programs: The Impact of Herd-Immunity , 2003, Medical decision making : an international journal of the Society for Medical Decision Making.
[56] Ben A. van Hout,et al. Discounting costs and effects: a reconsideration. , 1998 .
[57] C. Harvey. The reasonableness of non-constant discounting , 1994 .
[58] Jonathan Karnon,et al. Alternative decision modelling techniques for the evaluation of health care technologies: Markov processes versus discrete event simulation. , 2003, Health economics.
[59] C. Hollenbeak,et al. Rates and probabilities in economic modelling: transformation, translation and appropriate application. , 2007, PharmacoEconomics.
[60] Johan L Severens,et al. Discounting health outcomes in economic evaluation: the ongoing debate. , 2004, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[61] Murray Krahn,et al. Conceptualizing a Model , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[62] J. Caro,et al. Pharmacoeconomic analyses using discrete event simulation , 2012, PharmacoEconomics.
[63] B. van Hout. Discounting costs and effects: a reconsideration. , 1998, Health economics.
[64] J. Olsen,et al. On what basis should health be discounted? , 1993, Journal of health economics.
[65] Jeremy D Goldhaber-Fiebert,et al. Chapter 18: Public health policy for cervical cancer prevention: the role of decision science, economic evaluation, and mathematical modeling. , 2006, Vaccine.
[66] Andrew R Willan,et al. Time and expected value of sample information wait for no patient. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[67] J. Mauskopf,et al. Modelling the effect of conjugate vaccines in pneumococcal disease: cohort or population models? , 2010, Vaccine.